Table 3

Variables associated with 30-day mortality after VAP diagnosis in univariate analysis (n = 192)*

Characteristics
Nonsurvivors (n = 47)
Survivors (n = 145)
p value

Demographics



Age
62 ± 14
58 ± 17
0.12
Male gender
14 (30%)
40 (28%)
0.71
Characteristics before VAP



Charlson index
2 (1 to 3)
1 (0 to 3)
0.01
APACHE II on ICU admission
20 ± 8
21 ± 9
0.87
Shock on ICU admission
26 (55%)
50 (35%)
0.016
ARDS
21 (45%)
33 (23%)
0.005
RRT before VAP
17 (36%)
15 (10%)
< 0.001
Duration of mechanical ventilation before VAP, days
9 (5 to 16)
7 (3 to 14)
0.14
Number of infectious episodes before VAP
1 (1 to 1)
1 (1 to 1)
0.243
SOFA 2 days before VAP
7 (5 to 9)
5 (3 to 7)
0.001
Characteristics at diagnosis of VAP



SOFA at VAP
9 (5 to 11)
5 (4 to 8)
< 0.001
Delta SOFA
1 (0 to 4)
0 (-1 to 1)
< 0.001
VAP with shock
19 (40%)
22(15%)
< 0.001
Microbial aetiology of VAP



     MDR aetiology
19 (40%)
33 (23%)
0.02
     Gram-negative aetiology
40 (85%)
122 (84%)
0.39
Enterobacteriaceae
24 (62%)
70 (48%)
0.71
Pseudomonas aeruginosa
12 (26%)
39 (27%)
0.84
Non-fermenter other than P. aeruginosa
3 (6%)
2 (1%)
0.006
Other Gram-negative
1(2%)
11 (8%)
0.001
     Gram-positive aetiology
7(15%)
23(16%)
0.39
Staphylococcus aureus
7 (15%)
18 (12%)
0.37
Streptococcus pneumoniae
0
5 (4%)
0.01
Subsequent VAP
4 (9%)
30(21%)
0.08
Treatment characteristics



Appropriate therapy < 24 hours
38 (83%)
125(86%)
0.63
Appropriate therapy < 48 hours
43 (94%)
135 (93%)
0.99

*Data are presented as mean (± SD), median (25th to 75th percentile) or number (%).

Delta SOFA: SOFA two days after VAP minus SOFA two days before VAP.

† Other Gram-negative: Haemophilus. influenzae in 11, Moraxella catarrhalis in 1.

Data about antibiotic therapy were available in 187 patients (50 nonsurvivors and 137 survivors).

APACHE = Acute Physiology and Chronic Health Evaluation; ARDS = acute respiratory distress syndrome; ICU, Intensive Care Unit; MDR, Multidrug-resistant; RRT, Renal Replacement Therapy; SOFA = sequential organ failure assessment; VAP, Ventilator-associated Pneumonia.

Depuydt et al. Critical Care 2008 12:R142   doi:10.1186/cc7119